Star Therapeutics, a South San Francisco-based biotechnology company focused on discovery and development of therapies for diseases with significant unmet need, announced a $200.0M private financing that follows its July 2026 acquisition of subsidiary Vega Therapeutics. The financing was co-led by OrbiMed and Janus Henderson Investors, with participation from Agent Capital, Catalio Capital Management, Cormorant Asset Management, and New Leaf Vent [name truncated in article excerpt]. The excerpt provided does not disclose whether this represents a first or follow-on round, does not mention specific metrics such as clients, revenue, pipeline or employee count, and does not detail planned use of funds or expansion plans.